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Abstract
Nowadays, there is increasing evidence that some pathogenic bacteria can contribute to specific
stages of cancer development. The concept that bacterial infection could be involved in
carcinogenesis acquired a widespread interest with the discovery that H. pylori is able to establish
chronic infections in the stomach and that this infection is associated with an increased risk of
gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Chronic infections
triggered by bacteria can facilitate tumor initiation or progression since, during the course of
infection, normal cell functions can come under the control of pathogen factors that directly
manipulate the host regulatory pathways and the inflammatory reactions.
Renowned publications have recently corroborated the molecular mechanisms that link bacterial
infections, inflammation and cancer, indicating certain strains of Escherichia coli as a risk factor for
patients with colon cancer. E. coli is a normal inhabitant of the human intestine that becomes highly
pathogenic following the acquisition of virulence factors, including a protein toxin named cytotoxic
necrotizing factor 1 (CNF1). This toxin permanently activates the small GTP-binding proteins
belonging to the Rho family, thus promoting a prominent polymerization of the actin cytoskeleton
as well as a number of cellular responses, including changes in protein expression and functional
modification of the cell physiology. CNF1 is receiving an increasing attention as a putative factor
involved in transformation because of its ability to: (i) induce COX2 expression, an immediate-early
gene over-expressed in some type of cancers; (ii) induce a long-lasting activation of the
transcription factor NF-kB, a largely accepted marker of tumor cells; (iii) protect epithelial cells
from apoptosis; (iv) ensue the release of pro-inflammatory cytokines in epithelial and endothelial
cells; and (v) promote cellular motility. As cancer may arise through dysfunction of the same
regulatory systems, it seems likely that CNF1-producing E. coli infections can contribute to tumor
development.
This review focuses on the aspects of CNF1 activity linked to cell transformation with the aim of
contributing to the identification of a possible carcinogenic agent from the microbial world.
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Introduction
Bacterial infection and cancer
In the last century, cancer research thoroughly established
the role of major carcinogenic agents of different nature,
including infectious agents. However, although there is a
general agreement that some viruses, such as hepatitis B
virus (HBV), Epstein-Barr virus (EBV) and human papil-
loma virus (HPV) can cause cancer, the involvement of
bacteria in carcinogenesis remains controversial. The role
of viral infections in tumor onset is widely accepted
because of the direct action of single viral genes (onco-
genes) that result in cell transformation [1]. By contrast,
the molecular mechanism(s) by which bacteria might
promote tumorigenesis are still poorly characterized.
Hence, one of the main challenges, nowadays, is to define
the impact of bacterial infections as a cause of cancer and
eventually design strategies for their prevention and con-
trol.
Bacterial infections are usually believed to cause acute dis-
eases, but it is now becoming clear that some bacteria can
contribute to the establishment of chronic diseases,
including cancer [2]. The concept that bacterial infection
could be involved in carcinogenesis was first proposed in
the late nineteenth and early twentieth centuries, based
on the discovery of bacteria at the sites of tumors,
although there was no proof that the bacteria were in any
way causative [3]. Since then, the putative link between
chronic infection and cancer acquired a widespread inter-
est with the discovery that Helicobacter pylori is able to
establish chronic infections in the stomach and that this
infection is associated with an increased risk of gastric
adenocarcinoma [4] and mucosa associated lymphoid tis-
sue (MALT) lymphoma [5]. In this context, it is worth not-
ing that H. pylori is classified as a class I carcinogenic factor
[6]. Other chronic bacterial infections have been linked to
human carcinogenesis although the underlying mecha-
nisms remain to be defined (reviewed in [2]). The strong-
est epidemiological case is for Salmonella enterica serovar
typhi (S. typhi), the agent of typhoid, which can also lead
to chronic bacterial carriage in the gallbladder [7-11]. Sur-
veys of typhoid outbreaks have shown that those who
become carriers have an increased risk of developing
hepatobiliary carcinoma compared with people who have
had acute typhoid and have cleared the infection [9].
A recurring theme in the link between bacterial infection
and carcinogenesis is that of chronic inflammation, which
is often a common feature of persistent infection [2,12].
One of the key molecules that link chronic inflammation
and cancer is represented by the NF-kB family of transcrip-
tion factors [12,13]. In particular, different mouse studies
provide strong and direct genetic evidence that the classi-
cal, IKK-β dependent NF-kB activation pathway is indeed
a crucial mediator of tumor promotion [14-16]. This
pathway is triggered by bacterial and viral infections, as
well as by pro-inflammatory cytokines, such as TNF-α and
IL-1, all of which activate the IKK complex [17]. This com-
plex phosphorilates the NF-kB inhibitors IkBs, thereby
targeting them for proteosomal degradation and freeing
NF-kB to enter the nucleus and mediate transcription of
target genes. It is worth noting that many of the genes able
to mediate alterations characterizing a tumor cell are
under the transcriptional control of NF-kB (reviewed in
[18,19]). For example, the activity and expression of cyc-
lin D1, CDK2 kinase, c-myc, p21, p53 and pRb, which are
involved in the control of cell cycle and are altered in sev-
eral types of cancer, are NF-kB-dependent. The expression
of numerous cytokines, that are growth factors for tumor
cells (IL-1β, TNF, IL-6, EGF) are also regulated by NF-kB.
Tissue invasion and metastasis, two crucial events of
tumor progression, are regulated by NF-kB-dependent
genes, including metalloproteases (MMPs), urokinase
type of plasminogen activator (uPA), IL-8, the adhesion
molecules VCAM-1, ICAM-1 and ELAM-1. NF-kB is also
involved in the regulation of angiogenesis, the process by
which tumor cells promote neo-vascularization. Finally,
altered expression of genes involved in suppression of
apoptosis (i.e. Bcl-2 family members and IAP proteins), a
key feature of cancer cells, is often due to deregulated NF-
kB activity.
Concerning this last point, several pathogenic bacteria,
particularly those that can establish a persistent intracellu-
lar infection, activate NF-kB in the host cell and suppress
cell death, thus creating a niche in which the bacterium
can survive, in spite of the attempts of the host immune
system to destroy the infected cell [20]. As a consequence,
the suppression of apoptosis by a pathogen might also
allow a partially transformed cell to evade the self-destruc-
tive process and to progress to a higher level of transfor-
mation.
Another important feature of inflammation-associated
cancer is the production of reactive oxygen species (ROS)
and nitric oxide (NO) by inflammatory and epithelial
cells. This leads to increased mutations and altered func-
tions of important enzymes and proteins in inflamed tis-
sue, thus contributing to the multistage carcinogenetic
process [21]. For example, during a chronic H. pylori infec-
tion, production of ROS and nitroxides and the associated
inflammatory response are assumed to contribute to the
induction of a gastric carcinogenic process [22,23]. These
chemical species are mainly produced by inflammatory
cells to fight infection and are source of oxidative DNA
damage, thus contributing to carcinogenesis [22,23]. In
particular, it has been demonstrated that within 6 hours,
H. pylori infection had a mutagenic effect on gastric epi-
thelial cells [24]. The major form of oxidative DNA dam-
age is the formation of 8-oxoG lesions, specificallyInfectious Agents and Cancer 2008, 3:4 http://www.infectagentscancer.com/content/3/1/4
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repaired by the OGG1 DNA glycosylase. The inactivation
of this enzyme inhibits the level of inflammatory lesions
and abolishes the mutagenic effect induced by the infec-
tion at the gastric level, thus strengthening a close relation
between chronic inflammation and genotoxicity [24].
Bacterial toxins and cancer
As stated above, there is increasing evidence that some
pathogenic bacteria can contribute to specific stages of
cancer development. In particular, chronic infections trig-
gered by bacteria can facilitate tumor initiation or progres-
sion since, during the course of infection, normal cell
functions can undergo the control of factors released by
the pathogen [2]. These bacterial factors, namely virulence
factors, can directly manipulate the host regulatory path-
ways and the inflammatory reaction [3].
Bacteria express a wide range of virulence factors, includ-
ing protein toxins that have evolved to interact with
eukaryotic cellular machinery in a precise way. These tox-
ins interfere with key eukaryotic processes, such as cellular
signaling components, and some directly attack the
genome [25-27]. These last can damage DNA via different
mechanisms: i) directly by enzymatic attack, ii) indirectly
by provoking an inflammatory reaction that produces free
radicals, or even iii) by affecting DNA repair mechanisms.
Nougayrède and colleagues [28] have recently identified a
novel hybrid peptide-polyketide compound from
Escherichia coli that leads to DNA damage. This novel com-
pound is produced by pathogenic and, most interestingly,
commensal isolates. Although it is not yet clear how the
peptide-polyketide compound functions at the molecular
level, it is possible that it contributes to bacterial patho-
genesis and bacterially-induced carcinogenesis.
Any bacterial product that interferes with signaling, result-
ing in the disruption of the normal balance of growth, cell
division and apoptosis, could facilitate tumor promotion.
Similarly, the ability to promote anchorage-independent
growth could favor metastatic potential and lead to cancer
progression. So far, the best example of potentially carci-
nogenic toxin is H. pylori CagA that interferes with cellular
signaling mechanisms in a way that is characteristic of
tumor promoters. Indeed, CagA intracellularly interacts,
in a phosphorylation-dependent and independent way,
with many host proteins that regulate cell growth, motil-
ity and polarity, thus leading to gastric epithelial prolifer-
ation, cell-cell dissociation and increased cell scattering
and motility (for a review [29]). In particular, Bagnoli and
coworkers [30] showed that CagA is sufficient to disrupt
the mechanisms that maintain normal epithelial differen-
tiation, including cell adhesion, cell polarity, and the inhi-
bition of migration. Since the cellular behavior induced
by CagA is reminiscent of oncogenes that disrupt cytoskel-
etal signaling, the authors proposed that altered cell-cell
and cell matrix interactions may serve as an early event in
H. pylori-induced carcinogenesis [30]. Very recently, in
experimental studies dealing with H. pylori strains carrying
or not CagA, it has been demonstrated that this factor acti-
vates host cell survival and anti-apoptotic pathways to
overcome self-renewal of the gastric epithelium, thus
enhancing bacterial colonization of the stomach and
helping sustained H. pylori infection. In this context, it is
interesting to note that, patients infected with H. pylori
encoding the cag pathogeniticy island (PAI) are associated
with an increased risk of gastric cancer [31].
In addition to the link between H. pylori and stomach can-
cers, very recent studies evidenced that some other toxins
may contribute to bowel and urogenital tract cancers [3].
In this context, it has been reported that adherent and
invasive strains of Escherichia coli are a risk factor for
patients with pre-cancerous and cancerous colon diseases
[32,33]. Interestingly, in one of these studies, 3 out of 8
cancer-associated E. coli were reported to possess the cyto-
toxic necrotizing factor 1 (cnf1) gene [32], the gene coding
for the protein toxin CNF1. The aim of this review is to
highlight the main cell responses to CNF1, particularly
those related to signaling pathways linked to inflamma-
tion and to cell transformation.
CNF1 from E. coli: a protein toxin that activates 
the Rho GTPases
Although belonging to the normal human intestinal flora,
E. coli becomes highly pathogenic following the acquisi-
tion of genes coding for virulence factors, one of which
being CNF1 [34]. CNF1-producing E. coli strains are occa-
sionally detected in isolates from feces of children with
diarrhea [35-37], but, more frequently, are responsible of
extraintestinal infections, particularly in the urinary tract
(UTIs) [38-40]. Also, these strains can be detected in cases
of bacteraemia [41] and of meningitis in neonates [42].
CNF1, first described in 1983 by Caprioli and coworkers
as a toxin capable of causing multinucleation ("cyto-
toxic") in cultured cells (Fig. 1a, b) and necrosis in rabbit
skin ("necrotizing") [43,44], is a single-chain multido-
main protein toxin, containing a binding domain to a cell
receptor (N-terminal domain), a translocation domain
(middle domain) and an enzymatic one (C-terminal
domain) [45,46], which modifies a specific cellular target
in the host cell cytosol. CNF1 binds to the surface of cul-
tured epithelial cells with high affinity [47], and the 67-
kDa laminin receptor has been suggested (67LR) as a
putative receptor for CNF1 [48]. After binding to its recep-
tor, CNF1 is endocytosed and routed to an endosomal
compartment [47], from where the toxin injects its cata-
lytic activity into the cytosol [47], by using two hydropho-
bic structures present in the middle part of the CNF1
molecule [49].Infectious Agents and Cancer 2008, 3:4 http://www.infectagentscancer.com/content/3/1/4
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Different aspects of CNF1 activity on epithelial cells Figure 1
Different aspects of CNF1 activity on epithelial cells. (a-b) Transmission electron micrographs showing: a control 
mononucleated cell (a), and a CNF1-treated cell (b), bearing four nuclei in the cytoplasm. (c-d) Fluorescence micrographs of 
control (c) or CNF1-treated (d) cells stained for F-actin detection. CNF1-treated cells display polymerization of actin into 
stress fibers (asterisks) and prominent ruffles (arrows). (e-f) Scanning (e) and transmission (f) electron micrographs showing 
different stages of the internalization process of non-invasive bacteria by CNF1-treated cells. After being contacted by mem-
brane ruffles (e), bacteria are internalized within vacuoles (f). (g-h) Fluorescence micrographs of cells stained with an antibody 
that recognizes tubulin, the main component of microtubules. Note in h, an example of multipolar mitosis induced by CNF1. (i-
l) Fluoresce micrographs of control (i) and CNF1-treated (l) cells transfected with the Ds-Red plasmid to visualize mitochon-
drial organization. CNF1 induces the formation of elongated and interconnected mitochondria.Infectious Agents and Cancer 2008, 3:4 http://www.infectagentscancer.com/content/3/1/4
Page 5 of 9
(page number not for citation purposes)
The cytoplasmic target of CNF1 is represented by the Rho
GTPases, important molecular switches belonging to the
Ras superfamily, that cycle between an inactive GDP-
bound state and an active GTP-bound one, under the strict
control of activators (guanine nucleotide exchange fac-
tors, GEFs) and inactivators (GTPase-activating proteins,
GAPs) [50]. The conformational changes, induced by the
binding of GTP or GDP, occur inside two molecular
domains of the Rho proteins called switches  that are
responsible of the coupling of the G-proteins with their
downstream effectors (switch 1) and allow the interaction
of the activated GTPase with GAPs (switch 2). The enzy-
matic activity of CNF1 consists in the deamidation of a
specific glutamine residue located in the switch 2 domain
of the G proteins (glutamine 63 of Rho [51,52] or
glutamine 61 of Rac and Cdc42 [53]). This glutamine res-
idue is essential for the GTPase activity of Rho proteins,
either intrinsic or GAP-mediated [54]. By modifying
glutamine into glutamic acid, CNF1 impairs the role of
Rho GAP, allowing Rho proteins to be permanently
locked in their activated GTP-bound state and, thus,
enhancing the activity of these proteins on their effectors.
It is worth noting that the modification on Rho proteins
induced by CNF1 corresponds to the modification found
on Ras proteins in many tumors [55]. In fact, Rho
glutamine 63 corresponds to Ras glutamine 61, a well-
known residue that, after mutagenization, leads to a per-
manent activation of the molecule and to tumor onset.
CNF1 and Rho GTPases: actin remodeling and 
host cell invasion
The Rho GTPases are pivotal in controlling the actin
cytoskeleton architecture [50]. In fact, one of the first
described cell responses to CNF1 is a remarkable reorgan-
ization of the actin cytoskeleton in epithelial cells that
consists in the assembly of F-actin in prominent stress fib-
ers, membrane ruffles and filopodia [56] (Fig. 1c, d). The
prominent ruffling activity promoted by CNF1 permits
epithelial cells to behave as phagocytes, developing a mac-
ropinocytotic activity that allows the capture and engulf-
ment of different types of particles, including bacteria
[57,58]. This aspect is of particular relevance for the bac-
terial pathogenicity since the macropinocytic activity
ensued by CNF1 in epithelial cells may possibly represent
the route of entry of CNF1-producing E. coli, similarly to
what occurs with other intestinal pathogens (Fig. 1e). Fur-
thermore, upon activation by CNF1, the Rho GTPases
undergo sensitization to ubiquitylation and subsequent
proteosomal degradation [59], a process that would turn
off the ruffling process, thus allowing an efficient internal-
ization of bacteria inside the cells (Fig. 1f). It is worth not-
ing that the activity of CNF1, with its ability to switch on
the Rho GTPases and then coerce their degradation in the
proteasome, is somehow similar to the activity of the
intracellular bacterium Salmonella [60], for which a link
with cancer has been evidenced [9]. This bacterium first
activates the Rho GTPases, by the GEF-like toxin SopE, to
promote macropinocytosis that allows its entry into cells
and soon after, once inside, deactivates the GTPases via a
GAP-mimicking protein (SptP), thus allowing a moderate
threshold of Rho protein activation for a high invasion
efficiency [61].
By regulating the actin cytoskeleton, the Rho GTPases also
play a crucial role in certain aspects of the malignant phe-
notype, such as tumor cell motility, invasiveness and
metastasis [62]. Indeed, RhoC has been implicated as a
marker for highly angiogenic and aggressive breast cancer
with a high metastatic ability [63]. An additional clue in
favor of our hypothesis comes from the observation that
CNF1 provokes cell junctions disruption and strongly
enhances cellular motility in uroepithelial 804G cells
[59]. The augmented motility of epithelial cells highlights
another characteristic that somehow links this toxin to
cancer.
CNF1 hinders apoptosis via the pro-
inflammatory Akt/IKK/NF-kB pathway
It is also known that Rho proteins are crucially involved in
the development of inflammatory processes and that a
key player in the link existing between Rho, chronic
inflammation and cancer is the Nuclear Factor-kB (NF-
kB) [64]. As mentioned in the Introduction, NF-kB is rep-
resented by a group of structurally related and evolution-
arily conserved transcription factors involved in
regulating the expression of genes that control different
aspects of the tumor cell biology, including inflamma-
tion, cell growth, and suppression of apoptosis (reviewed
in [65]). Tumor cells can show elevated NF-κB-regulated
transcription, which can inhibit TNF-α-induced apoptosis
through the up-regulation of the anti-apoptotic proteins
of the Bcl-2 family.
In this context, we previously reported that CNF1 can acti-
vate the nuclear factor-kB (NF-kB) [66] in epithelial cells.
Such an activation, is responsible for the ability of the
toxin to stimulate the expression of pro-inflammatory fac-
tors and to protect host cell from apoptotic stimuli. As
concerns the pro-survival activity, we have shown that
CNF1 can increase the expression of proteins related to
cell adhesion (integrins, Focal Adhesion Kinase, cadher-
ins, catenins), thus improving cell spreading and the abil-
ity of cells to adhere to each other and to the extracellular
matrix [67]. In fact, prolonged cell survival, together with
increased adhesion to matrix components might have sig-
nificant biological consequences and affect the tumori-
genic potential of epithelial cells. Moreover, CNF1
protects epithelial cells against the drop of the mitochon-
drial membrane potential provoked by UVB radiation andInfectious Agents and Cancer 2008, 3:4 http://www.infectagentscancer.com/content/3/1/4
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increases the expression of the anti-apoptotic members of
the Bcl-2 family, Bcl-2 and Bcl-XL  [68]. Although the
causal relationship between Bcl-2 and mitochondrial
membrane potential has not yet been clarified, we have
very recently demonstrated that the up-regulation of the
anti-apoptotic protein Bcl-2 somehow controls the mito-
chondrial morphology, and that this depends on the acti-
vation of the pro-inflammatory Rac1/PI3K/Akt/IKK/NF-
kB pathway [69]. In fact, besides blocking the activity of
the pro-apoptotic members of Bcl-2 family, Bcl-2 is
involved in the regulation of mitochondrial morphology,
since Bcl-2-over-expressing mitochondria present both
increased volume and structural complexity [70]. In living
cells, mitochondria continuously divide (fission) and fuse
(fusion) with one another [71] and Bcl-2 family members
are involved in these processes, the pro-apoptotic mem-
bers regulating fission whereas the anti-apoptotic regulat-
ing fusion of mitochondria [72]. In this context, we very
recently demonstrated that CNF1 can induce, in epithelial
cells, the formation of a complex network of elongated
and interconnected mitochondria with an increased aver-
age length [[69]; Fig. 1i, l]. Importantly, Bcl-2 silencing
reduces the ability of CNF1 to protect cells against apop-
tosis and also prevents the CNF1-induced mitochondrial
changes. Therefore, since the mitochondrial remodeling is
of direct relevance for the role of these organelles in cell
physiology and the mitochondrial dysfunction can con-
tribute to a number of human disorders, including cancer
[73], the role of CNF1 as a factor favoring transformation
can be further supported by this novel finding.
As concerns inflammation, CNF1 ensues the transcription
and release of pro-inflammatory cytokines, such as IL-6,
IL-8 and TNF-α in uroepithelial [74] and endothelial [75]
cells, probably contributing to the establishing of the
inflammatory process due to CNF1-producing E. coli. The
pro-inflammatory role of CNF1 is also supported by the
demonstration that the toxin strongly up-regulate the
transcription of cyclooxygenase- 2 (COX-2) [76], an
immediate-early gene induced in response to pro-inflam-
matory cytokines, tumor promoters, and growth factors
and over-expressed in cancers of the lung, colon, stomach,
and breast [77-79].
Conclusion
On the whole, it appears that CNF1 touches some of the
signaling pathways that are engaged by carcinogens and
tumor promoters, as schematized in Fig. 2. Particularly
relevant are the activation of the transcription factor NF-
κB, the pro-survival activity, the increased expression of
RNA messengers for COX-2 and pro-inflammatory
cytokines as well as the augmented cell motility. In addi-
tion, CNF1 impairs the cytokinesis, thus leading to multi-
nucleation [44,56], induces nuclear segmentation,
amitotic cell division, multipolar mitosis (Fig. 1g, h) [80],
and modulates autophagy [81], cellular phenomena that
are frequently observed in different types of cancer cells,
and blocks the cell cycle G2/M transition in epithelial cells
[82]. The ability of CNF1 to block the cell cycle progres-
sion suggests a strategy that permits to contain the host
damage, and to induce specific cellular responses rather
than rapid cell death. This could in turn facilitate the bac-
terial invasion of underlying tissues. The activity of CNF1,
with its ability to switch on the Rho GTPases and then
coerce their degradation in the proteasome, probably
renders the CNF1-producing E. coli intracellular parasites,
hence permitting their potentially harmful and presuma-
bly transforming activity inside the cell, where they can
escape the host immune system attack. Finally, it is worth
noting that CNF1 activity on cells shares several properties
with CagA from the carcinogenic bacterium H. pylori,
which can be indicated as the best example of a poten-
Hypothetic model on how the pro-inflammatory CNF1 activ- ity can be connected to cancer Figure 2
Hypothetic model on how the pro-inflammatory 
CNF1 activity can be connected to cancer. CNF1-
dependent Rho activation stimulates NF-κB nuclear translo-
cation and trans-activation, through the classical Akt/IKK-
mediated pathway. NF-κB induces the transcription of genes 
coding for proteins involved in inflammation and apoptosis, 
that is the pro-inflammatory molecules IL-6, IL-8, TNF-α and 
Cox-2, and anti-apoptotic factors, such as Bcl-2. This last also 
causes elongation and enrichment of the mitochondrial net-
work, an aspect somehow linked to transformation. On the 
other hand, by mean of its activity on the actin cytoskeleton 
organization, CNF1 is able to provoke cell junctions disrup-
tion and to strongly enhance cellular motility, a phenomenon 
strictly linked to invasiveness and metastasis.Infectious Agents and Cancer 2008, 3:4 http://www.infectagentscancer.com/content/3/1/4
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tially carcinogenic toxin [29]. In Table 1, the cellular
effects of E. coli CNF1 and those of the major virulence
factors (VacA and CagA) of H. pylori are compared.
Hence, taking altogether, we can hypothesize that once
secreted by epithelium-associated E. coli, CNF1 switches
on the Rho GTPases, initiating a pathway that leads to the
actin cytoskeleton reorganization, but also to the activa-
tion of NF-κB, which in turn enter the nucleus and causes
the transcription of anti apoptotic factors as well as pro-
inflammatory cytokines. Production and secretion of pro-
inflammatory factors recruits cells of the immune system
creating an inflammatory environment. Epithelial cells
with the Rho GTPases modified by CNF1 in a way that
corresponds to the modification found on Ras proteins in
many tumors [55], continue to grow without undergoing
apoptosis in an environment rich of inflammatory factors.
This can account, finally, for promotion or increase of the
neoplastic risk.
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